[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
November 25, 1939


JAMA. 1939;113(22):1969-1970. doi:10.1001/jama.1939.02800470045013

The use of acetarsone as an antisyphilitic drug which could be taken by mouth has been reviewed recently by Pillsbury and Perlman,1 who studied 187 cases of congenital syphilis at the Sigma Clinic of the Children's Hospital, University of Pennsylvania School of Medicine. Their conclusions corroborate the previous statements made by the Council on Pharmacy and Chemistry2 concerning the use of acetarsone in the treatment of syphilis. The investigators emphasize that acetarsone, although an active antisyphilitic agent by mouth, is less rapid in action than arsphenamine and is inferior to both arsphenamine and bismuth preparations in arresting congenital syphilis. In their series of cases they found a high incidence of reactions. They concluded, indeed, that adequate experimental background for determination of the toxicity and spirocheticidal effect of individual lots of acetarsone is not available. In addition they observed that regularity of attendance of patients at the clinic was